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Purpose:  Experimental autoimmune uveoretinitis (EAU) is an animal model of posterior uveitis and heme 
oxygenase-1 (HO-1) is a well-known anti-oxidant factor. However, there is no report a protective role of 
HO-1 on EAU in vivo. To verify that HO-1 is induced in EAU by interphotoreceptor retinoid-binding protein 
(IRBP), that an HO-1 inducers ameliorates the associated inflammation, and that an HO-1 inhibitor 
exacerbates this inflammation.
Methods: Forty four Lewis rats were given either 40 mol/kg hemin or 40 mol/kg SnPP (tin protoporphyrin 
IX) by intraperitoneal injection and twenty two uveitis control rats were injected with 0.5 mL of saline once 
daily 5-20 days after IRBP immunization inducing EAU. Three normal control rats were used for Western 
blotting and ELISA assay of HO-1. The clinical uveitis signs of inflammation were scored in the three groups 
from 0 to 4 on alternate three days. To confirm the clinical results, histological and immunohistochemical 
stain of HO-1 were performed on the day of peak inflammation and Western blotting and ELISA assay of 
HO-1 were performed on 6
th, 12
th and 18
th day after IRBP immunization.
Results: Hemin, an inducer of HO-1, ameliorated the clinical signs of EAU. In contrast, SnPP-treated rats 
show that the severity of the clinical sign were exacerbated at the peak period of the disease. These results 
are roughly compatible with histological, immunoblotting, and immunohistochemical evaluations and an 
ELISA assay of HO-1.
Conclusions: We suggest that HO-1 plays an important protective role in EAU.
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Experimental autoimmune uveoretinitis (EAU) is a 
prototypic T-cell-mediated autoimmune disease in which the 
target tissue is the neural retina. EAU is characterized by 
granuloma formation in the neural retina, destruction of 
photoreceptor cells, and blindness.
1,2 The pathology of EAU 
in an animal model of putative autoimmune etiology serves 
as a model for sight‐threatening posterior uveitis or 
panuveitis such as Vogt-Koyanagi-Harada (VKH) disease, 
Behcet's disease, birdshot retinochoroidopathy, sympathetic 
ophthalmia, and ocular sarcoidosis.
3 There was a report that 
oxidative stress induced HO-1 exclusively in the Müller cells 
of mouse retina in vitro study,
4 but others report that HO-1 
expressed in the rat retina against light damage.
5 Ohta et al.
6 
reported that there was a protective role of HO-1 against 
endotoxin-induced uveitis (EIU). They revealed HO-1 and 
HO-2 was expressed in iris and ciliary body (ICB). EIU is 
an animal model corresponds to anterior uveitis that is 
improved easily by topical steroid therapy. However, this 
study is first time to disclose that HO-1 has an important role 
against EAU that correspond to posterior uveitis.
Oxidative stress is the fundamental mechanism underlying 
many different diseases, and is implicated in the pathogenesis 
of many neurological pathologies. Organisms use a multitude 
of endogenous antioxidant mechanisms to defend against the 
deleterious effects of oxidative stress. Heme oxygenase-1 
(HO-1) is one such potent mechanism. HO-1 protein, also 
called heat shock protein 32 (hsp32), is the rate-limiting 
enzyme in the catabolism of heme to biliverdin, free iron, and 
CO. Its expression has been correlated with protection against 
oxidative stress and ischemia. HO-1 activity is increased in 
whole animal tissues and in cultured cells following treatment 
with heme, metals, and inflammatory cytokines, as well as 
under hypoxic and oxidative conditions. HO-1 is also induced JU Jang, et al. EFFECTS OF HO-1 INDUCER AND INHIBITOR ON EAU
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by various stimuli, including heat shock, hyperoxia, and 
oxidative stress, and represents a powerful endogenous 
protective mechanism against free radicals in a variety of 
pathological conditions, including inflammation, ischemic 
stroke, and many neurodegenerative diseases.
7
Hemin is an iron containing metalloporphyrin. Chemically, 
hemin is represented as chloro (7,12-diethenyl-3,8,13,17- 
tetramethyl-21H, 23H-porphine 2,18‐dipropanoato (2-) -N
21, 
N
22, N
23, N
24) iron. Hemin is substrate for the HO-1 enzyme. 
HO enzyme is up-regulated by its substrate hemin.
8 SnPP is 
tin-protophophyrin IX, a potent competitive inhibitor of HO, 
regulates HO by a dual control mechanism that is potently 
inhibiting the HO enzyme activity while enhancing the 
synthesis of HO enzyme protein.
9
In this study, we examined the expression of HO-1 in 
lesions of EAU to evaluate the involvement of HO-1 in EAU, 
and demonstrated that hemin, an inducer of HO-1, 
ameliorates EAU clinically. To confirm these clinical effects, 
histological, western blotting, and immunohistochemical 
analyses of HO-1 were performed.
Materials and Methods
Animals and reagents: A total of 69 adult male Lewis rats 
with body weights between 150 and 200 g were obtained 
from SLC, Inc. (Hamamatsu, Japan). All experiments were 
conducted in accordance with the ARVO Statement for the 
Use of Animals in Ophthalmic and Vision Research. 
Interphotoreceptor retinoid-binding protein (IRBP)-derived 
peptides were synthesized and purified by Peptron Co., Ltd. 
(Daejeon, Korea), using the peptide sequence of bovine IRBP 
determined and reported by Borst et al.
10 A epitope of peptide 
1169-1191 (PTARSVGAAD……GSSWEGVGVVPDV) was 
purchased from Sigma (USA). The rats were divided into 
four groups: 22 served as IRBP-treated controls (IRBP- 
control group); 22 were treated with the HO-1 inducer, hemin 
(hemin-treated group); and 22 were treated with the HO-1 
inhibitor, tin protoporphyrin IX (SnPP, SnPP-treated group). 
Other three rats were used normal control for Western 
blotting and ELISA assay of HO-1.
Immunization (EAU induction with IRBP) and hemin or 
SnPP treatments: The rats were immunized by subcutaneous 
injections of 150 g of IRBP in 100 L of emulsion with 
complete Freund's adjuvant (1:1.5, v/v) that had been 
supplemented with Mycobacterium tuberculosis to a final 
concentration of 2.5 mg/mL, without pertussis toxin. Animals 
were given either 40 mol/Kg hemin (Frontier Scientific Inc., 
USA), or 40 mol/Kg SnPP (Frontier Scientific Inc.) by 
intraperitoneal injection once daily for 5-20 days after 
immunization. IRBP control rats received injections of the 
same volume of saline on the same schedule. The volume 
injected into each rat was 0.5 mL.
Clinical assessment of EAU: The incidence and severity of 
EAU were examined with a biomicroscope on day 3 of the 
pre‐clinical stage of the disease, and thereafter to assess 
disease development. The clinical signs of inflammation were 
scored on grades of 0 to 4. Grade 0 indicated no disease; 
grade 1 indicated enlargement of the iris vessel; grade 2 
indicated cellular infiltrates in the anterior chamber; grade 3 
indicated fibrin deposition around the pupil and little 
hypopyon; and grade 4 indicated fibrin plugging of the pupil 
and development of severe inflammatory hypopyon.
11
ELISA assay of HO-1: Three rats of each group were 
killed in the early stage of the disease (6
th day), during peak 
disease activity (12
th day), in the late stage of EAU (18
th day) 
and three rats as normal controls. One eye was for ELISA 
and the other eye is for Western blot of HO-1. Cornea, 
aqueous humor and lens were removed and a remnant in the 
scleral shell was emulsified. The emulsion was used to assay 
ELISA kit following the protocol. Briefly, The specimen was 
homogenized, extraction buffer and centrifuged, and the 
supernatant was used for the assay. One of the rat 
monoclonal anti-heme oxygenase-1 was immobilized onto 
the microtiter plate and blocked against non-specific binding. 
Samples and standards were incubated in the microtiter plate. 
The second step is to wash the plate and add HO-1 labeled 
with peroxidase (POD). During this incubation, rat HO-1 is 
bound to anti-HO-1 on one side and tagged on the other by 
POD-anti-HO-1. The reaction between POD and substrate 
results in color development with intensities proportional to 
the amount of rat HO-1 present in samples and standards. 
The amount of rat HO-1 was measured the absorbance using 
an EIA plate reader.
Western blotting analysis: At the same time as the ELISA 
specimens were prepared, the other eyes of the rats were 
prepared for western blotting analysis. The specimens were 
homogenized in lysis buffer containing protease inhibitors,
12 
and the lysate collected for western blotting analysis. Protein 
levels were determined by immunoblotting with antibodies 
directed against mouse HO-1. Briefly, 80 μg of lysate 
supernatant was separated by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membrane (Amersham, Piscataway, NJ) using 
a semidry transfer apparatus (Bio-Rad, Hercules, CA). The 
membranes were incubated at 4℃ overnight with 5% milk 
in 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.05% 
Tween 20 (TBST buffer). After the membranes were washed 
with TBST, they were incubated with constant shaking for 
1 h at room temperature with a 1:1,000 dilution of anti-HO-1 
antibody. Mouse anti‐HO-1 antibodies were obtained from 
StressGen Biotechnologies Corp. (Victoria, BC, Canada). The 
membranes were then washed and probed with horseradish- 
peroxidase-conjugated donkey anti-mouse IgG (Amersham) at 
a dilution of 1:2,000. Chemiluminescent detection was 
performed with the Amersham ECL detection kit according 
to the manufacturer's instructions.
Histologic and immunohistochemistry: One rat of each 
groups at the stage of peak disease were prepared for 
histology and immunohistochemistry. Formalin-fixed and 
paraffin-embedded tissue specimens were cut to a thickness Kor J Ophthalmol Vol.21, No.4, 2007
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Fig. 1. Clinical evaluation of uveitis signs
The hemin-treated group had a lower grade of inflammation
than the IRBP-control group; the SnPP-treated group had a 
higher grade than the IRBP-control group. Each group has 20 
rats until 6
th day, 19 rats from 9
th to 18
th day and 17 rats at 
21
st day. Score and standard deviation was marked as above. 
Clinical signs of uveitis were significantly different between 
SnPP-treated group and IRBP-control group from 6 days after 
immunization. In addition, there were significant difference 
between Hemin-treated group and IRBP-control group from 12
days to 18 days after immunization.
IRBP-control group: immunization with IRBP and daily 
injection of saline.
Hemin-treated group: immunization with IRBP and daily 
injection of Hemin 10 μMole.
SnPP-treated group: immunization with IRBP and daily 
injection of SnPP 10 μMole.
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Fig. 2. Western blot analysis and normalized ratio of HO-1 and
β-actin as internal control HO-1 protein expression in the three
groups on days 6th, 12th and 18th after immunization; HO-1 
was strongly expressed in the hemin-treated group. HO-1 was 
expressed less in the SnPP-treated group than in the IRBP- 
treated group. C; normal control, S; SnPP, H; hemin, I; IRBP.
of 4 μm. HO-1 was detected in the tissue specimens 
described above with a monoclonal antibody (StressGen 
Biotechnologies Corp.) directed against HO-1. Briefly, 
paraformaldehyde-fixed tissue sections were thawed and 
incubated in excess enzyme substrate (3% H2O2 for 
peroxidase) for 10 min at room temperature. The primary 
antibody was applied at a dilution of 1:200 overnight at 4℃ 
and incubated with a streptavidin-conjugated secondary 
antibody. HO-1 was counter-stained with Gill's hematoxylin 
for 3 seconds.
Statistical analysis: Clinical uveitis grading was evaluated 
by Chi-square test and a value of p<0.05 was considered 
statistically significant.
Results 
Effects on Clinical Symptoms of EAU 
The clinical symptoms of EAU were evaluated in the three 
groups on alternate three days over the entire 21 days. As 
shown in Fig. 1, EAU was apparent on day 6 in the SnPP- 
treated group, reached a state of peak uveitis on day 12, and 
then eventually diminished until day 21. The hemin-treated 
group had a lower grade of inflammation than the 
IRBP-control group; the SnPP-treated group had a higher 
grade than the IRBP-control group. Each group has 22 rats 
until 6th day, 19 rats from 9th to 18th day and 15 rats at 
21st day. Clinical signs of uveitis were statistically 
significantly different between SnPP- treated group and 
IRBP-control group from 6days after immunization. And 
there were significant difference between Hemin-treated 
group and IRBP-control group only from 12 days to 18 days 
after immunization (Fig. 1).
Western blotting of HO-1 
HO-1 was strongly expressed in the hemin-treated group 
at 12th peak day and 18th day. However, HO-1 was less 
expressed in the SnPP-treated group than in the IRBP-treated 
group. And IRBP-treated control group was more expressed 
than normal control due to inflammation response. SnPP 
treated group has been similarly expressed to normal control 
(Fig. 2).
ELISA assay of HO-1 
This test was performed three rats on each groups on 6th, 
12th, and 18th days after IRBP immunization. In a Hemin- 
treated rat, HO-1 was markedly high compared to an IRBP- 
control rat, whereas in an SnPP-treated rat, HO-1 was below 
to the level of the IRBP-control rats (Fig. 3).JU Jang, et al. EFFECTS OF HO-1 INDUCER AND INHIBITOR ON EAU
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Fig. 3. HO-1 enzyme assay in each IRBP-control, 
SnPP-treated, and Hemin-treated rats This test was performed 
three samples of one rat on each group on 6th, 12th, and 
18th days after IRBP immunization. In a Hemin-treated rat, 
HO-1 was markedly high compared to an IRBP-control rat, 
whereas in an SnPP-treated rat, HO-1 was below to the level
of the IRBP-control rat.
Fig. 4. Effects on the immunohistochemical aspects of EAU. Upper left; In the IRBP-control rat, HO-1 was occasionally expressed
in the ganglion cell layer (arrow head) and inner nuclear layer (arrow). Upper right; In the hemin-treated rat, HO-1 was expressed 
more strongly in the ganglion cell layer (arrow head) and the inner nuclear layer (arrow) than in the IRBP-control rat. Lower left;
There was scanty expression of HO-1 (arrow head) in the SnPP-treated rat. Lower right; Normal control.
Immunohistochemical Detection of HO-1 
In the IRBP-control rat, HO-1 was occasionally expressed 
in the ganglion cell layer and inner nuclear layer. In the 
hemin-treated rat, HO-1 was expressed more strongly in the 
ganglion cell layer and the inner nuclear layer than in the 
IRBP-control rat. There was scanty expression of HO-1 in the 
SnPP-treated ratIn the IRBP-treated control group. In the 
normal control, there was no HO-1 expression (Fig. 4).
Discussion
The uveitis is an intractable disease in the field of 
ophthalmology. Steroids, anti‐inflammatory agents or 
immunosuppressive agents have been used to reduce the 
uveitis inflammation, even though they have many 
complications.
13 For a new therapeutic modality, exact 
mechanism of uveitis and animal model of uveitis might be 
established.
Our results clearly show that HO-1 is expressed in EAU. 
As in other diseases, HO-1 plays a protective role in EAU. 
Hemin, an inducer of HO-1, ameliorated the clinical signs of 
EAU. In contrast, SnPP-treated rats have more severe clinical 
signs of inflammation especially at the peak period of the 
disease. These results demonstrate that HO-1 plays an 
important protective role in EAU.
Over the past decade, a kind of small heat shock protein, 
HO-1, has been implicated as a cytoprotective enzyme 
against oxidative injuries.
14 HO-1 is well known as the Kor J Ophthalmol Vol.21, No.4, 2007
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32-kDa heat shock protein.
15 It is now considered a powerful 
cellular defense mechanism against oxidative stress,
16 and 
plays a protective role in many stress-mediated diseases. For 
example, a recent experiment demonstrated that HO-1 
induction attenuates experimental Parkinson's disease.
17 The 
antioxidant effects of HO-1 are said to be multifactorial and 
dependent on the diverse dimensions of HO activity. HO-1 
catalyzes the rate-limiting step in heme catabolism, 
generating free iron, CO, and bilirubin.
18 Bilirubin is regarded 
today as a potent antioxidant substance in vitro and as a very 
effective physiological antioxidant in vivo. Bilirubin 
scavenges superoxide and peroxyl radicals,
19 and possesses 
antimutagenic and anticomplement properties.
20 CO, another 
heme metabolite that is considered a gaseous messenger, also 
has anti-inflammatory effects involving the mitogen-activated 
protein (MAP) kinase pathway.
21 CO also inhibits the release of 
some cytotoxic cytokines.
22 HO-1-mediated heme degradation 
also appears to act in the negative feedback regulation of the 
production of iNOS-derived NO, and ameliorates the 
cytotoxicity caused by the free radical NO and its reactive 
derivative peroxynitrate (ONOO
-).
23 All these properties 
contribute to the potent antioxidant effects of HO-1. A variety 
of stimuli, including oxidative stress, ischemia reperfusion, 
endotoxin, and cytokines, has been shown to induce HO-1 
expression in various tissues. HO-1 catalyzes the rate-limiting 
step in the degradation of heme to yield equimolar amounts 
of biliverdin, carbon monoxide (CO), and iron.
15 Recently, it 
has been reported that HO-1 is increased in iris-ciliary body 
(ICB) of EIU rat.
6
A central question is why HO-1 is important in EAU. 
Oxidative stress resulting from the toxic effects of reactive 
oxygen species plays a remarkably common role in the 
mechanisms of a wide variety of diseases.
24 There is evidence 
that oxidative stress is important in the pathogenesis of 
experimental autoimmune encephalitis (EAE) and multiple 
sclerosis.
25 HO-1 is also considered a factor in the formation 
and resolution of inflammatory autoimmune lesions of the 
nervous system.
26 In fact, the majority of reports concerning 
HO and autoimmunity have focused on HO-1.
This study shows that HO-1 is induced in neural retina 
especially ganglion cell and inner nuclear layer when hemin 
was introduced. Hemin-induced HO-1 plays an protective 
role in the EAU animal model. And SnPP makes the uveitis 
inflammation signs aggravate clinically and that was 
supportive to other experiments. However, further study 
would be needed to confirm the role of HO-1 on EAU by 
statistically proved methods. In conclusions, we have shown the 
expression of HO-1 in EAU and demonstrated its protective role 
in this disease, especially at the peak of the illness.
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